Get startedLog in
    Picture of SynAct Pharma AB logo

    SYNACT — SynAct Pharma AB News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapMomentum Trap
    All News

    Development And Commercialization Partnership With Hipolabor In Brazil

    Picture of SynAct Pharma AB logoSynAct Pharma AB
    19/08/2026 06:04
    BRIEF-Synact Pharma Signs Term Sheet For Co-Development And Commercialization Partnership With Hipolabor In Brazil
    Aug 19 (Reuters) - SynAct Pharma AB SYNACT.ST:
    • SIGNS TERM SHEET FOR CO-DEVELOPMENT AND COMMERCIALIZATION PARTNERSHIP WITH HIPOLABOR IN BRAZIL
    • COMMERCIAL LICENSE AGREEMENT INCLUDES 50-50 PROFIT SHARE AND SALES MILESTONES FOR INITIAL $200 MILLION NET SALES
    • CO-DEVELOPMENT ARRANGEMENT INCLUDES 50-50 SPLIT ON DEVELOPMENT COST FOR RESOMELAGON APPROVAL IN BRAZIL
    Source text: ID:nMFN4HPjDf
    Further company coverage: SYNACT.ST

     (Gdansk Newsroom)
     ((gdansk.newsroom@thomsonreuters.com;  +48 58 769 66 00;))

    Recent news on SynAct Pharma AB

    See all news